Thomas, David X.
Bajaj, Sumali
McRae-McKee, Kevin
Hadjichrysanthou, Christoforos
Anderson, Roy M.
Collinge, John
Funding for this research was provided by:
UCLH Biomedical Research Centre
Medical Research Council (MR/L023784/2, MR/L023784/2, MR/L023784/2)
Article History
Received: 11 February 2020
Accepted: 14 July 2020
First Online: 3 September 2020
Competing interests
: Prof Roy M. Anderson completed 10 years as a Non-Executive director of GlaxoSmithKline (GSK) in June 2019. GSK played no part in this research, its funding or the preparation of the manuscript. Prof John Collinge is a shareholder and Director of D-Gen Limited, an academic spin-out company working in the field of prion disease diagnosis, decontamination and therapeutics. The remaining authors declare no competing interests.